| Autor: |
Giannitrapani, L, Liacata A, Ferrara T, Mirarchi, L, Montalto, FA, Puccia, F, Minissale, G, Capitano, A, Terranova, A, Montalto, G, Soresi, M |
| Přispěvatelé: |
Giannitrapani, L, Liacata, A, Ferrara, T, Mirarchi, L, Montalto, FA, Puccia, F, Minissale, G, Capitano, A, Terranova, A, Montalto, G, Soresi, M |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Popis: |
Background:Among the endpoints of antiviral therapy with DAAs in HCV related liver cirrhosis (LC-HCV) in addition to the eradication of the virus there are the regression of fibrosis and of portal hypertension. For this reason we evaluated in LC-HCV patients and sustained virological response (SVR) to DAAs therapy the behavior of the AST to Platelet Ratio Index (APRI) (indirect marker of fibrosis) and of two ultrasound (US) signs of portal hypertension: caliber of the portal vein (cPV ) and longitudinal diameter of the spleen (LDS) Methods:132 patients with LC-HCV at baseline (BL), at three months (PostT3) and 12 months (PostT12) after the end of therapy, performed liver function tests and platelet count, US at BL, at PostT3 and at PostT12 and the liver stiffness (LS) measurement with Fibroscan at BL. The diagnosis of LC was histological in 12% of patients, in 88% was done by LS, US and endoscopy. Genotype 1b was present in 79% of the patients. When we performed the statistical analysis, 90 patients included in the study were at PostT12. We used the t-Student test for paired data, the Spearman's rho and the chi-square test when appropriated. Results: cPV at BL was significantly higher than at postT3 (P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
